PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Biotechnology

Life Sciences

Pharmaceutical

PHAXIAM Therapeutics

PHAXIAM Therapeutics' headquarters in LYON, France

Jerome Bailly

Vaishali Mistry

Carole Sansoz

Jonathan Blachier

The Leadership Team at PHAXIAM Therapeutics is responsible for setting the strategic direction, overseeing daily operations, and ensuring regulatory compliance as the company develops innovative phage-based treatments for resistant bacterial infections. This team drives corporate development, quality assurance, human resources, and medical strategy, while managing financial and operational activities to align with PHAXIAM's goals and regulatory standards.

Leadership Team

The Research and Development Team at PHAXIAM Therapeutics is dedicated to the discovery and advancement of phage-based therapies targeting resistant bacterial infections. This team conducts laboratory research, leads clinical studies, and manages projects to innovate and optimize treatment options for critical pathogens. Utilizing expertise in microbiology and clinical development, they aim to bring effective solutions to tackle the growing challenge of antibiotic resistance in healthcare settings.

Research and Development Team

The Regulatory Affairs Team at PHAXIAM Therapeutics is responsible for navigating the complex regulatory landscape to ensure that innovative phage therapies meet all necessary compliance standards. This team collaborates closely with research and development, quality assurance, and external regulatory bodies to facilitate the approval processes for clinical trials and product commercialization, ultimately helping to bring groundbreaking treatments for resistant bacterial infections to market.

PHAXIAM Therapeutics

Org chart

Teams

Leadership Team

Research and Development Team

Regulatory Affairs Team

Offices

PHAXIAM Therapeutics

Org chart

Teams

Leadership Team

Research and Development Team

Regulatory Affairs Team

Offices

Related companies